Ayça İribaş çelik

Dr. Ayça İribaş çelik


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2025 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
ETEdanur Topal
Edanur Topal
BKBilal Kovan
Bilal Kovan
AÇAyça İribaş çelik
Ayça İribaş çelik
SKSerkan Kuyumcu
Serkan Kuyumcu
MBMert Basaran
Mert Basaran
YSYasemin Sanli
Yasemin Sanli
Purpose: This study aimed to evaluate the personalized dosimetric approach by calculating the cumulative renal absorbed dose (cRD) and assessing its impact on renal functions in patients diagnosed with metastatic castration-resistant prostate cancer who underwent four or more cycles of [177Lu] Lu-PSMA − 617 therapy. Methods: The study included 110 patients who received ≥ 4 cycles of [177Lu] Lu-PSMA − 617 therapy. Whole-body static and abdominal SPECT-CT imaging was performed at 4, 24, and 96 h post-administration. Kidney function was assessed using dynamic renal scintigraphy and biochemical tests conducted prior to treatment. Estimated glomerular filtration rate (eGFR) levels were calculated using the CKD-EPI formula before each treatment cycle and at the 6th week post-treatment. Results: Pearson correlation analysis reveal no significant relationship between cRD and CKD-EPI values (p >.05). No significant differences were observed between pre-treatment CKD-EPI levels and those measured after the 4th, 5th, 6th, 7th, and 8th cycles (p >.05). Among patients reaching a cRD of 23 Gy, a statistically significant difference was observed between pre- and post-treatment CKD-EPI values (p <.05). Of the 13 patients exceeding cRD of 28 Gy, five maintained CKD-EPI levels above 90 mL/min/1.73 m2 post-treatment. Conclusion: Despite treatment-related declines in eGFR levels, our findings indicate that a personalized dosimetric approach may enable extended cycles of [177Lu] Lu-PSMA-617 therapy with manageable nephrotoxicity. Considering the significant inter-patient variability, establishing universal absorbed dose-response relationships remains challenging. Prospective multicenter studies are crucial to refining toxicity thresholds and advancing tailored treatment strategies to optimize safety and efficacy.

29 September 2024 in Pediatric Blood & Cancer
Verified
Journal Article
Open access
PDF file
RKRejin Kebudi
Rejin Kebudi
Ulku Miray YildirimUlku Miray Yildirim
Ulku Miray Yildirim
AÇAyça İribaş çelik
Ayça İribaş çelik
STSamuray Tuncer
Samuray Tuncer
Background: Optic pathway gliomas (OPG) are rare tumors in children. Lesion extent, visual functions, neurofibromatosis 1 (NF1), and age are factors that guide treatment. This study evaluates the clinical characteristics, treatment, and outcome of children and adolescents with OPG treated over a 31‐year period in a single center. Methods: Ninety‐five patients with OPG diagnosed between January 1990 and December 2021 were retrospectively evaluated. First‐line chemotherapy regimen consisted of vincristine and carboplatinum for 1 year. Radiotherapy was not used as first‐line treatment and tried to be avoided in the ones who progressed after first‐line treatment. Results: Ninety‐five children (44 male, 51 female) with a median age of 52 (1–216) months were evaluated. Sixty‐three (66.3%) had NF1 and 10 (10,5%) diencephalic syndrome. The most common presenting symptoms were visual abnormalities and/or proptosis, nistagmus, and behavioral changes. Twenty‐one (22.1%) patients with NF1 had stable disease throughout the follow‐up period and received no treatment. Sixty‐three of 74 patients received treatment at diagnosis and 11 due to progression during follow‐up. Only one adolescent received radiotherapy at progression. Patients who progressed, received further line systemic treatment (vinblastine; bevacizumab; vincristine–cisplatinum–etoposide). Ten‐year overall survival in all patients, in patients with NF1, and without NF1 were 97.2%, 98%, and 95.8% ( p > .05), respectively; 10‐year progression‐free survival (PFS) in all patients, in patients with NF1, and without NF1 were 71.6%, 85.7%, and 54.2% ( p = .001), respectively. Conclusions: In children with symptomatic/progressive OPG, chemotherapy consisting of vincristine–carboplatinum (VC) is effective. Radiotherapy may be avoided, especially in patients with NF1.

22 September 2021 in Child's Nervous System
Verified
Journal Article
Closed access
PDF file
YAYavuz Aras
Yavuz Aras
DBDuygu Dolen burak
Duygu Dolen burak
AÇAyça İribaş çelik
Ayça İribaş çelik
GKGozde Kılıç
Gozde Kılıç
RKRejin Kebudi
Rejin Kebudi
AIAli Nail İzGi
Ali Nail İzGi

28 January 2021 in İstanbul Tıp Fakültesi Dergisi
Verified
Journal Article
Open access
PDF file
DSDuygu Has Simsek
Duygu Has Simsek
EIEMINE GOKNUR ISIK
EMINE GOKNUR ISIK
CCCaner Civan
Caner Civan
ZÖZeynep Gözde Özkan
Zeynep Gözde Özkan
SKSerkan Kuyumcu
Serkan Kuyumcu
YŞYasemin Şanlı
Yasemin Şanlı
İstanbul Üniversitesi Yayın Projesi

27 December 2022 in Batı Karadeniz Tıp Dergisi
Verified
Journal Article
Open access
PDF file
MPMetin Pehli̇van
Metin Pehli̇van
AÇAyça İribaş çelik
Ayça İribaş çelik
BBBilge Bi̇lgi̇ç
Bilge Bi̇lgi̇ç
MBMert Başaran
Mert Başaran
MEMeltem Ekenel
Meltem Ekenel
Amaç: Yumuşak doku sarkomları genellikle ekstremitelerde veya retroperitonda görülür, %5-10 hastada ise baş boyun bölgesinde görülür. Yumuşak doku sarkomları baş ve boyun kanserlerinin <%1’den azını oluşturur. Çalışmamızda tedavi edilen baş boyun lokalize yumuşak doku sarkomlu hastalarını retrospektif inceledik. Gereç ve Yöntemler: Onkoloji polikliniğinde; baş ve boyun lokalizasyonlu yumuşak doku sarkomu nedeniyle tedavi almış 18 yaşın üstündeki hastalar alınmıştır. Kemik sarkomları ile 18 yaşından küçük hastalar çalışmaya alınmamıştır. Ocak 2000 ile Aralık 2020 arasındaki hasta dosyaları incelenip çalışmaya uygun olan hastalar çalışmaya alınmış ve analiz edilmiştir. Bulgular: Çalışmamıza 21 hasta dahil edildi. 12 hasta (%57) kadın, dokuz hasta erkekti (%43). Hastaların yaş ortalaması 53.8’di (18-88). Sekiz hasta (%38) iğsi hücreli sarkom (alt tiplendirme yapılmamış), beş hasta (%23,8) anjiyosarkom, bir hasta (%4,7) epiteloid malign periferik sinir kılıf tümörü, bir hasta (%4,7) interdigiting retikulum hücreli sarkom, bir hasta (% 4,7 dermatofibrosarkom), bir hasta (% 4,7) malign fibröz histiyositoma, bir hasta (%4,7) sinovyal sarkom, bir hasta (%4,7) leiomyosarkom, bir hasta (%4,7) dendritik hücreli sarkom bir hasta (%4.7) ise ameloblastik fibrosarkom histolojisine sahipti. 11 hasta (%52) lokal, altı hasta (%28,5) lokal ileri hastalık ve dört hasta (%19) ise metastatik hastalığa sahipti. dokuz hastada (%42,8) hastalık nüksetmişti. Dört hastada (%19) lokal nüks meydana geldi, beş hastada uzak metastaz oldu. Hastalık nüksü için median süre 11 (3 – 18) aydı. Medyan toplam sağkalım 41 aydı (5-217). Sonuç: Baş ve boyun yumuşak doku sarkomları oldukça nadir görülen evrelemesi bile tam olarak oturmamış, oldukça kötü prognozlu bir malignitedir. Tedavisi temel olarak cerrahidir. Adjuvan kemoterapi ve radyoterapi tam olarak üzerinde uzlaşılmış tedaviler değildir Aim: Soft tissue sarcomas are usually seen in the extremities or the retroperitoneum, and are seen in the head and neck region in 5-10% of patients. Soft tissue sarcomas account for <1% of head and neck cancers. We retrospectively reviewed the patients with head and neck localized soft tissue sarcoma treated in our study. Material and Methods: In the oncology clinic; Patients over the age of 18 who received treatment for soft tissue sarcoma localized in the head and neck were included. Patients younger than 18 years of age with bone sarcomas were not included in the study. The patient files between January 2000 and December 2020 were examined and the patients eligible for the study were included and analyzed. Results: 21 patients were included in our study. 12 patients (57%) were female and nine patients (43%) were male. The mean age of the patients was 53.8 (18-88). Eight patients (38%) spindle cell sarcoma (not subtyped), five patients (23.8%) angiosarcoma, one patient (4.7%) epithelioid malignant peripheral nerve sheath tumor, one patient (4.7%) interdigiting reticulum cell sarcoma, one patient (4.7% dermatofibrosarcoma), one patient (4.7%) malignant fibrous histiocytoma, one patient (4.7%) synovial sarcoma, one patient (4.7%) leiomyosarcoma, one patient (4.7%) 4.7) had dendritic cell sarcoma and one (4.7%) patient had ameloblastic fibrosarcoma histology. 11 patients (52%) had local, six (28.5%) locally advanced disease, and four (19%) had metastatic disease. disease relapsed in nine patients (42.8%). Local recurrence occurred in four patients (19%), and distant metastases occurred in five patients. The median time for disease recurrence was 11 (3 – 18) months. The median overall survival was 41 months (5-217). Conclusion: Head and neck soft tissue sarcomas are a rare malignancy with a poor prognosis and an incomplete staging. Its treatment is mainly surgical. Adjuvant chemotherapy and radiotherapy are not fully agreed upon treatments.

Verified
Journal Article
Open access
PDF file
EDElif Bilgin Doğru
Elif Bilgin Doğru
SESelçuk Erdem
Selçuk Erdem
HSHilal Oguz soydinc
Hilal Oguz soydinc
AÇAyça İribaş çelik
Ayça İribaş çelik
DDDerya Duranyıldız
Derya Duranyıldız
Prostate cancer is a clinically heterogeneous disease. Since PSA is not cancer-specific, and due to the bone metastases seen in the advanced stage and bone deformations caused by hormone therapy, it is necessary to use new biomarkers. Formin-like-protein 1 (FMNL1), a member of the formin protein family, is of great importance in actin polymerization, cell attachment, and migration processes. p21-activated kinase 1 (PAK1) proteins, members of the PAK protein kinases, play a role in cytoskeletal organization, as well as regulating other cellular activities such as cell survival, mitosis, and transcription. In our study, plasma and urine samples of 60 prostate cancer patients and 20 healthy controls were studied using RT-PCR and ELISA methods. No statistical difference was found between FMNL1 mRNA and protein expression levels of patients and controls in both plasma and urine samples (p > 0.05). There was no statistical difference between PAK1 mRNA expression levels of patients and controls in plasma and urine samples (p > 0.05). While no significant difference was found in PAK1 protein levels in plasma samples (p > 0.05), it was found to be lower in urine samples of patients compared to the control group (p = 0.00). Both marker molecules have low expression levels in early-stage PCa.